UBS Group’s NexImmune, Inc. Common Stock NEXI Stock Holding History

UBS Group’s Portfolio NEXI Stock Details NEXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-638	Closed	-$1.76K	–	10475
2024 Q2	$1.76K	Buy	638 +637	+63,700%	+$2.14K	﹤0.01%	8498
2024 Q1	$6	Hold	1	–	–	﹤0.01%	9137
2023 Q4	$2	Sell	1 -1	-50%	-$3	﹤0.01%	9194
2023 Q3	$10	Hold	2	–	–	﹤0.01%	9219
2023 Q2	$14	Hold	2	–	–	﹤0.01%	8716
2023 Q1	$19	Sell	2 -663	-100%	-$6.96K	﹤0.01%	9429
2022 Q4	$3.99K	Buy	665 +80	+14%	+$998	﹤0.01%	9408
2022 Q3	$8K	Buy	585 +483	+474%	+$14.2K	﹤0.01%	8773
2022 Q2	$4K	Buy	102 +53	+108%	+$3.28K	﹤0.01%	9175
2022 Q1	$5K	Sell	49 -178	-78%	-$13.1K	﹤0.01%	9191
2021 Q4	$26K	Buy	+227	New	+$54.5K	﹤0.01%	7556
2021 Q3	–	Sell	-43	Closed	-$18K	–	10252
2021 Q2	$18K	Sell	43 -32	-43%	-$14.7K	﹤0.01%	7460
2021 Q1	$36K	Buy	+75	New	+$40.8K	﹤0.01%	6862

Other funds holding NEXI

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

UBS Group's NEXI Position: Q3 2024 in Review

UBS Group sold out of NexImmune, Inc. Common Stock (NEXI) in Q3 2024, closing a stake of 638 shares — an estimated $1.76K sold.

UBS Group first reported a position in NEXI in Q1 2021 and held it in 13 quarters. The position peaked at $36K in Q1 2021. 1 fund tracked by Wall St. Rank holds NEXI as of Q3 2024.

UBS Group reported no remaining NexImmune, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
UBS Group sold 638 NexImmune, Inc. Common Stock shares in Q3 2024, an estimated $1.76K.
UBS Group first reported a position in NexImmune, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
UBS Group's NexImmune, Inc. Common Stock position peaked at $36K in Q1 2021.
1 fund tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.